Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab biomarker study in treatment-naive advanced NSCLC
NL-OMON55382Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoints: Association between baseline tissue TMB or blood TMB and objective response rate and Correlation between baseline tissue TMB and blood TMB. Started Jul 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55382.